Traders should monitor the upcoming Pre-NDA meeting with the FDA in Q2 2026 and NDA submission in H2 2026 as key catalysts. The strong clinical data, robust cash runway, and first-in-class potential support upside, though biotech regulatory risk remains.
Price Chart
Executive Summary
Palvella Therapeutics reported full-year 2025 financial results and provided a significant corporate update highlighting positive Phase 3 data for QTORIN™ rapamycin in microcystic lymphatic malformations, a $230 million equity raise, and an expanded clinical pipeline. The company is on track for an NDA submission in 2026 and a potential U.S. launch in 2027, positioning QTORIN™ as a first-in-class therapy for a rare disease with no approved treatments.
Key Financial Metrics
Key Facts
- Positive Phase 3 SELVA trial results for QTORIN™ rapamycin in microcystic LMs: met primary endpoint with p<0.001, 95% of patients improved, and no drug-related serious adverse events.
- Raised $230.0 million in gross proceeds via an oversubscribed equity offering in February 2026, bringing pro forma cash to $274 million as of December 31, 2025.
- NDA submission for QTORIN™ rapamycin in microcystic LMs on track for second half of 2026, with potential FDA approval in first half of 2027.
- Initiation of Phase 3 trial for cutaneous venous malformations and Phase 2 trials for angiokeratomas and DSAP all planned between Q2–H2 2026.
- Net loss for 2025 was $41.7 million ($3.71 per share), up from $17.4 million ($7.83 per share) in 2024, driven by increased R&D and G&A spending.
Financial Impact
Pro forma cash increased to $274 million post-financing, funding accelerated development and U.S. launch readiness. R&D expenses more than doubled to $22.8 million in 2025.
Risk Factors
- Regulatory risk: NDA approval is not guaranteed despite Breakthrough Therapy and Orphan designations.
- Dilution: The equity raise increased shares outstanding to 15.7M, potentially pressuring the stock if future financings are needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265348 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 144 | $155.47 $132.47 | ▼ −14.79% | ▼ −13.61% | $132.47 (−14.79%) |
Aug 9, 2026 7w ago | Institutional Cluster | $152.22 $157.00 | ▲ +3.14% | ▲ +4.05% | $132.47 (−12.97%) |
Aug 4, 2026 8w ago | 8-K | $151.99 $150.55 | ▼ −0.95% | ▲ +0.29% | $132.47 (−12.84%) |
Jul 30, 2026 9w ago | Press Release | $150.19 $150.33 | ▲ +0.09% | ▼ −3.87% | $132.47 (−11.80%) |
Jul 28, 2026 9w ago | Press Release | $142.84 $148.24 | ▲ +3.78% | ▲ +0.40% | $132.47 (−7.26%) |
Jun 30, 2026 13w ago | 8-K | $152.82 $141.77 | ▼ −7.23% | ▼ −6.20% | $132.47 (−13.32%) |
Jun 22, 2026 14w ago | Press Release | $118.84 $157.24 | ▲ +32.31% | ▲ +32.46% | $132.47 (+11.47%) |
Jun 16, 2026 15w ago | 8-K | $110.12 $149.68 | ▲ +35.92% | ▲ +35.72% | $132.47 (+20.30%) |
Jun 11, 2026 16w ago | Institutional Cluster | $106.38 $151.04 | ▲ +41.98% | ▲ +40.09% | $132.47 (+24.53%) |
May 15, 2026 20w ago | 8-K | $114.24 $116.51 | ▲ +1.99% | ▼ −0.13% | $132.47 (+15.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access